FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,276 letters match. Newest first.

  1. MolluscumRx, Inc.

    FDA told MolluscumRx, Inc. of Orlando, Florida that its molluscum lotion and soap are unapproved new drugs sold with unsupported cure claims.

    High risk
  2. Nature’s Innovation, Inc.

    FDA warned Nature’s Innovation over unapproved drugs marketed for molluscum and shingles, including a kit for children.

    High risk
  3. Thrasio, LLC D/B/A ZymaDerm

    FDA warned Thrasio/ZymaDerm that its ZymaDerm for Molluscum is an unapproved new drug marketed without FDA approval.

    High risk
  4. Walmart, Inc

    FDA warned Walmart over selling Naturasil Molluscum Treatment Kit, an unapproved new drug for molluscum.

    High risk
  5. Amazon.com, Inc

    FDA warned Amazon that it sold four unapproved drugs claiming to treat molluscum contagiosum, including products marketed for children.

    High risk
  6. K. Boeun Pharmaceutical Co., Ltd.

    K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

    High risk
  7. International Laboratories Corp. Ltd.

    International Laboratories Corp. Ltd. failed manufacturing-practice rules for OTC drugs, including component identity testing and quality-unit oversight.

    High risk
  8. Angela M. Stupi, M.D.

    Clinical investigator Angela M. Stupi, M.D. enrolled ineligible subjects and injected study drug at wrong body sites in two trials.

    High risk
  9. CalmCo LLC previously named Ketomi LLC

    FDA warns CalmCo that Colic Calm and Colic Calm + are unapproved new drugs for infants.

    High risk
  10. ALVA-AMCO Pharmacal Companies, LLC

    FDA warns ALVA-AMCO that Nauzene Kids, a children’s nausea drug, is an unapproved new drug.

    High risk
  11. Laavo Clean, S.A. de C.V.

    Laavo Clean's alcohol-free hand sanitizers had wrong benzalkonium chloride strength and were refused at US border.

    High risk
  12. AstraZeneca Pharmaceuticals LP

    FDA says AstraZeneca's Breztri sales aid made false or misleading efficacy claims, making the COPD drug misbranded.

    Low
  13. Denison Pharmaceuticals, LLC

    Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

    High risk
  14. Cergomex Imports, LLC

    Cergomex Imports, an over-the-counter drug manufacturer, refused FDA records requests for its Sanetto Hands Sanitizer Gel.

    Medium
  15. GTP International Corp

    GTP International, a Mesquite, TX maker of OTC hand sanitizer, refused FDA's repeated requests for manufacturing records.

    Medium
  16. Fancystage Unipessoal, LDA

    Portugal OTC drug maker Fancystage Unipessoal skipped identity testing of high-risk ingredients and lacked quality-unit control, FDA says.

    High risk
  17. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  18. KM Pharmaceutical Co. Ltd.

    FDA says KM Pharmaceutical refused to provide drug records and placed all its drugs on import alert.

    High risk
  19. Tan Alize Kozmetik Ve Temizlik Urunleri

    FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

    High risk
  20. Sangleaf Pharm., Co. Ltd.

    Sangleaf Pharm failed to give FDA requested records for OTC drugs, including children's toothpaste, at risk of DEG/EG contamination.

    High risk
  21. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk
  22. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  23. Skyline Herbals Private Limited

    FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.

    High risk
  24. Daxal Cosmetics Private Limited

    FDA warns Daxal Cosmetics for refusing records on over-the-counter drugs, including toothpaste, at risk for diethylene glycol and ethylene glycol contamination.

    High risk
  25. Orchid Lifesciences

    FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.

    High risk
  26. US Specialty Formulations, LLC

    US Specialty Formulations, a drug compounder registered as an outsourcing facility, made sterile compounded drugs under insanitary conditions.

    High risk
  27. Intas Pharmaceuticals Limited

    FDA warned Intas Pharmaceuticals about serious manufacturing-quality violations, including data integrity failures and inaccurate environmental monitoring, at its India drug plant.

    High risk
  28. Baxter Healthcare Corporation

    FDA warned Baxter over CGMP violations at its India plant, including inadequate endotoxin and visual inspection investigations for sterile injectables.

    High risk
  29. Centaur Pharmaceuticals Private Ltd.

    FDA says Centaur Pharmaceuticals drugs were adulterated due to inadequate cleaning and cross-contamination.

    High risk
  30. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  31. Iso-Tex Diagnostics, Inc.

    FDA warns Iso-Tex Diagnostics over manufacturing violations that risk contamination of sterile radiopharmaceutical drugs.

    High risk
  32. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  33. LXR Biotech, LLC

    FDA says LXR Biotech, a contract maker of an OTC drug, shipped batches without testing components or finished product.

    High risk
  34. Jamol Laboratories, Inc.

    FDA found Jamol Laboratories making a nasal emollient under insanitary conditions and without adequate quality control, lab testing, or process validation.

    High risk
  35. Gadget Island, Inc.

    Gadget Island sold three male enhancement products containing undeclared tadalafil and sildenafil without FDA approval.

    High risk
  36. Wise Women’s Choice

    FDA warned Wise Women’s Choice that its natural birth control cream is an unapproved new drug sold with pregnancy-prevention claims.

    High risk
  37. Fuller Industries Inc.

    FDA warns Fuller Industries over current good manufacturing practice violations in OTC hand soaps and sanitizers, including quality oversight and ingredient testing.

    High risk
  38. Centaur Pharmaceuticals Private Ltd.

    FDA warns Centaur Pharmaceuticals over manufacturing practice failures in active ingredients, including records and cleaning.

    High risk
  39. Sunshine Trading Company, Inc. dba Nova Tea and Nova Kratom

    FDA warned Nova Kratom that its kratom products are unapproved new drugs marketed to treat opioid addiction and withdrawal.

    High risk
  40. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  41. Lydia Co. Ltd.

    Lydia Co. Ltd. submitted mismatched drug listing data for eight products, leading FDA to remove them from its NDC Directory.

    Low
  42. Suprimo Imports

    FDA warns Suprimo Imports that AK Forte and Bob Marley CannaKing are unapproved, misbranded drugs; AK Forte contains hidden prescription ingredients.

    High risk
  43. Chengdu KeCheng Fine Chemicals Co., Ltd.

    FDA placed Chengdu KeCheng's APIs on import alert after it ignored FDA records requests.

    High risk
  44. Safe Chain Solutions, LLC

    Safe Chain Solutions, a wholesale drug distributor, failed to verify suspect Biktarvy and bought from unauthorized trading partners.

    High risk
  45. Randy J. Epstein, M.D./Chicago Cornea Consultants, Ltd.

    FDA warns Dr. Epstein/Chicago Cornea Consultants over trial without IND and inadequate drug records.

    High risk
  46. Warrior Labz SARMS

    FDA warned Warrior Labz SARMS that it sells unapproved new drugs, including SARMs and injectables, with drug claims online.

    High risk
  47. Pharmacy Plus, Inc., dba Vital Care Compounder

    FDA warned Pharmacy Plus (Vital Care Compounder) that its sterile compounded drugs were made under insanitary conditions, risking contamination.

    High risk
  48. Carolina Infusion

    FDA warns Carolina Infusion over compounded drugs made without valid prescriptions and under insanitary conditions, including sterile products.

    High risk
  49. Mr. Lulu LLC

    FDA warned Mr. Lulu LLC of Claremont, California, that its OTC sunscreen drops were adulterated: no release testing, no identity testing, no batch records.

    High risk
  50. Mobeen Mazhar, M.D.

    FDA warned clinical investigator Dr. Mobeen Mazhar for enrolling ineligible subjects, missing safety reports, and consenting a subject late in drug trials.

    High risk